Cargando…
Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment
The synthesis of a new nanogel drug carrier system loaded with the anti-cancer drug doxorubicin (DOX) is presented. Poly(2-oxazoline) (POx) based nanogels from block copolymer micelles were cross-linked and covalently loaded with DOX using pH-sensitive Schiff’ base chemistry. DOX loaded POx based na...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976466/ https://www.ncbi.nlm.nih.gov/pubmed/29854280 http://dx.doi.org/10.18632/oncotarget.24806 |
_version_ | 1783327181396508672 |
---|---|
author | Hoelzer, Doerte Leiske, Meike N. Hartlieb, Matthias Bus, Tanja Pretzel, David Hoeppener, Stephanie Kempe, Kristian Thierbach, René Schubert, Ulrich S. |
author_facet | Hoelzer, Doerte Leiske, Meike N. Hartlieb, Matthias Bus, Tanja Pretzel, David Hoeppener, Stephanie Kempe, Kristian Thierbach, René Schubert, Ulrich S. |
author_sort | Hoelzer, Doerte |
collection | PubMed |
description | The synthesis of a new nanogel drug carrier system loaded with the anti-cancer drug doxorubicin (DOX) is presented. Poly(2-oxazoline) (POx) based nanogels from block copolymer micelles were cross-linked and covalently loaded with DOX using pH-sensitive Schiff’ base chemistry. DOX loaded POx based nanogels showed a toxicity profile comparable to the free drug, while unloaded drug carriers showed no toxicity. Hemolytic activity and erythrocyte aggregation of the drug delivery system was found to be low and cellular uptake was investigated by flow cytometry and fluorescence microscopy. While the amount of internalized drug was enhanced when incorporated into a nanogel, the release of the drug into the nucleus was delayed. For in vivo investigations the nanogel drug delivery system was combined with a metronomic treatment of DOX. Low doses of free DOX were compared to equivalent DOX loaded nanogels in a xenograft mouse model. Treatment with POx based nanogels revealed a significant tumor growth inhibition and increase in survival time, while pure DOX alone had no effect on tumor progression. The biodistribution was investigated by microscopy of organs of mice and revealed a predominant localization of DOX within tumorous tissue. Thus, the POx based nanogel system revealed a therapeutic efficiency despite the low DOX concentrations and could be a promising strategy to control tumor growth with fewer side effects. |
format | Online Article Text |
id | pubmed-5976466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-59764662018-05-31 Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment Hoelzer, Doerte Leiske, Meike N. Hartlieb, Matthias Bus, Tanja Pretzel, David Hoeppener, Stephanie Kempe, Kristian Thierbach, René Schubert, Ulrich S. Oncotarget Research Paper The synthesis of a new nanogel drug carrier system loaded with the anti-cancer drug doxorubicin (DOX) is presented. Poly(2-oxazoline) (POx) based nanogels from block copolymer micelles were cross-linked and covalently loaded with DOX using pH-sensitive Schiff’ base chemistry. DOX loaded POx based nanogels showed a toxicity profile comparable to the free drug, while unloaded drug carriers showed no toxicity. Hemolytic activity and erythrocyte aggregation of the drug delivery system was found to be low and cellular uptake was investigated by flow cytometry and fluorescence microscopy. While the amount of internalized drug was enhanced when incorporated into a nanogel, the release of the drug into the nucleus was delayed. For in vivo investigations the nanogel drug delivery system was combined with a metronomic treatment of DOX. Low doses of free DOX were compared to equivalent DOX loaded nanogels in a xenograft mouse model. Treatment with POx based nanogels revealed a significant tumor growth inhibition and increase in survival time, while pure DOX alone had no effect on tumor progression. The biodistribution was investigated by microscopy of organs of mice and revealed a predominant localization of DOX within tumorous tissue. Thus, the POx based nanogel system revealed a therapeutic efficiency despite the low DOX concentrations and could be a promising strategy to control tumor growth with fewer side effects. Impact Journals LLC 2018-04-27 /pmc/articles/PMC5976466/ /pubmed/29854280 http://dx.doi.org/10.18632/oncotarget.24806 Text en Copyright: © 2018 Hoelzer et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Hoelzer, Doerte Leiske, Meike N. Hartlieb, Matthias Bus, Tanja Pretzel, David Hoeppener, Stephanie Kempe, Kristian Thierbach, René Schubert, Ulrich S. Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment |
title | Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment |
title_full | Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment |
title_fullStr | Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment |
title_full_unstemmed | Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment |
title_short | Tumor targeting with pH-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment |
title_sort | tumor targeting with ph-responsive poly(2-oxazoline)-based nanogels for metronomic doxorubicin treatment |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976466/ https://www.ncbi.nlm.nih.gov/pubmed/29854280 http://dx.doi.org/10.18632/oncotarget.24806 |
work_keys_str_mv | AT hoelzerdoerte tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT leiskemeiken tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT hartliebmatthias tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT bustanja tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT pretzeldavid tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT hoeppenerstephanie tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT kempekristian tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT thierbachrene tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment AT schubertulrichs tumortargetingwithphresponsivepoly2oxazolinebasednanogelsformetronomicdoxorubicintreatment |